- The event will highlight positive results from the TELLOMAK
Phase 2 Trial with lacutamab in heavily pretreated patients with
relapsed and refractory Sézary syndrome which have been selected
for oral presentation at the American Society of Hematology (ASH)
Annual Meeting
- Virtual KOL event will be held on Tuesday, December 12, 2023
at 7:00AM PST (4:00PM CET)
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that it
will host a virtual KOL (Key Opinion Leader) event on lacutamab, a
first-in-class anti-KIR3DL2 antibody currently in development for
cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma
(PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM
CET).
The event will feature Prof. Pierluigi Porcu, M.D., Director,
Division of Hematologic Malignancies and Hematopoietic Stem Cell
Transplantation, Sidney Kimmel Cancer Center, Jefferson Health,
Philadelphia, United States, and principal investigator in the
TELLOMAK Phase 2 study, who will discuss Sézary syndrome data from
the TELLOMAK trial following oral presentation at the American
Society of Hematology (ASH) 2023 Annual Meeting. Prof. Porcu is a
Lymphoma-focused hematologic oncologist with a long track record of
advocacy and education for patients with cutaneous lymphoma. Sonia
Quaratino, M.D., PhD, Chief Medical Officer of Innate Pharma, will
host the call.
As disclosed in the abstract release on November 3, positive
data from the Phase 2 TELLOMAK study in Sézary syndrome will be
reported at the ASH 2023 Annual Meeting on December 9. The ASH
abstract states that lacutamab showed promising clinical activity
and an overall favorable safety profile in the heavily pre-treated
post-mogamulizumab patient population with a median of six prior
lines of therapy. In the Intention to treat population (ITT), the
global confirmed objective response rate (ORR) was 37.5% (21/56).
ORR in the skin was 46.4% (26/56) and ORR in the blood was 48.2%
(27/56). Median progression-free survival was 8.0 months (95% CI
4.7-21.2). Additional data will be presented at the ASH 2023 Annual
Meeting.
Virtual KOL Event
Details
Tuesday, December 12, 2023 at
7:00AM PST (4:00PM CET)
The live webcast will be
available at the following link:
https://events.q4inc.com/attendee/341836372
Participants may also join via
telephone using the following registration link:
https://registrations.events/direct/Q4I90753
This information can also be
found on the Investors section of the Innate Pharma website,
www.innate-pharma.com. A replay of the webcast will be available on
the Company website for 90 days following the event.
About Lacutamab
Lacutamab is a first-in-class anti-KIR3DL2 humanized
cytotoxicity-inducing antibody that is currently in clinical trials
for treatment of cutaneous T-cell lymphoma (CTCL), an orphan
disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous
lymphomas of T lymphocytes have a poor prognosis with few
efficacious and safe therapeutic options at advanced stages.
KIR3DL2 is an inhibitory receptor of the KIR family, expressed
by approximately 65% of patients across all CTCL subtypes and
expressed by up 90% of patients with certain aggressive CTCL
subtypes, in particular, Sézary syndrome. It is expressed by up to
50% of patients with mycosis fungoides and peripheral T-cell
lymphoma (PTCL). It has a restricted expression on normal
tissues.
Lacutamab is granted European Medicines Agency (EMA) PRIME
designation and US Food and Drug Administration (FDA) granted Fast
Track designation for the treatment of patients with relapsed or
refractory Sézary syndrome who have received at least two prior
systemic therapies. Lacutamab is granted orphan drug status in the
European Union and in the United States for the treatment of
CTCL.
About TELLOMAK:
TELLOMAK (NCT03902184) is a global, open-label, multi-cohort
Phase 2 clinical trial recruiting patients with Sézary syndrome and
mycosis fungoides (MF) in the United States and Europe.
Specifically:
- Cohort 1: lacutamab being evaluated as a single agent in
approximately 60 patients with Sézary syndrome who have received at
least two prior systemic therapies, including mogamulizumab. The
Sézary syndrome cohort of the study could enable the registration
of lacutamab in this indication.
- Cohort 2: lacutamab being evaluated as a single agent in
patients with MF that express KIR3DL2, as determined at baseline
with a Simon 2-stage design.
- Cohort 3: lacutamab being evaluated as a single agent in
patients with MF that do not express KIR3DL2, as determined at
baseline, with a Simon-2 stage design.
- All comers: lacutamab being evaluated as a single agent in
patients with both KIR3DL2 expressing and non-expressing MF to
explore the correlation between the level of KIR3DL2 expression and
treatment outcomes utilizing a formalin-fixed paraffin embedded
(FFPE) assay under development as a companion diagnostic.
The trial is now fully enrolled. The primary endpoint of the
trial is objective global response rate. Key secondary endpoints
are progression-free survival, duration of response, overall
survival, quality of life, pharmacokinetics and immunogenicity and
adverse events.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231126099215/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
過去 株価チャート
から 5 2024 まで 6 2024
Innate Pharma (NASDAQ:IPHA)
過去 株価チャート
から 6 2023 まで 6 2024